NICE Updates Medical Cannabis Guidance for Chronic Pain Patients
The National Institute for Health and Care Excellence has revised its guidance on prescribing medical cannabis for patients living with chronic pain, opening the door for more NHS and private prescriptions.
The National Institute for Health and Care Excellence (NICE) has issued updated guidance on the use of medical cannabis products for patients suffering from chronic pain conditions, marking a significant shift in how clinicians approach this treatment option across England and Wales.
What the Updated Guidance Covers
The revised framework acknowledges the growing body of clinical evidence supporting the use of cannabinoid-based medicines for a range of chronic pain conditions, including neuropathic pain, fibromyalgia, and pain associated with multiple sclerosis. Clinicians are now encouraged to consider cannabis-based treatments earlier in the patient pathway, particularly where conventional therapies have not delivered adequate relief.
- Neuropathic pain patients may be considered for cannabis-based therapy after two failed conventional treatments
- Chronic pain associated with cancer or MS is explicitly highlighted in the new framework
- Prescribers must still operate under specialist oversight, but referral pathways have been simplified
- Patient-reported outcome measures are now recommended for ongoing monitoring
Impact on UK Patients
For the estimated 15 million people in the UK living with chronic pain, this guidance update represents meaningful progress. Many patients have previously faced barriers to accessing medical cannabis through formal channels, often relying on private clinics at considerable personal expense. Specialists at licensed clinics across the UK have broadly welcomed the changes.
If you are a chronic pain patient considering medical cannabis, you can explore available chronic pain treatment options or find a specialist through our clinic directory.
What Patients Should Do Next
If you believe you may qualify under the revised guidance, the recommended first step is to speak with your GP and request a specialist referral. You can also consult our guide to getting a prescription for a detailed walkthrough of the process. For those interested in available products, our CBD-dominant strain listings provide a useful overview of what is currently accessible to UK patients. The full NICE guidance document is available through NHS England and applies to all prescribers operating within England and Wales.
